Navigation Links
Studies show LAM patients participate in clinical trials to help others, not themselves
Date:5/14/2009

CINCINNATITwo recent studies by researchers at the University of Cincinnati (UC) bring to light interesting findings about the diagnosis of the rare lung disease Lymphangioleiomyomatosis ( LAM) and the reasons LAM patients participate in research studies.

Brent Kinder, MD, Frank McCormack, MD, and Jared Hagaman, MD, working with colleagues in the division of pulmonary, critical care and sleep medicine at UC, found that patients with LAM were more likely to participate in clinical trials because of a shared cause and a feeling of altruism, as opposed to personal benefit.

In addition, this team found that CT scans given to young women who come to the emergency room for the first time with a collapsed lung are cost-effective and beneficial.

These findings will be presented at the American Thoracic Society International Conference in San Diego May 15-20.

LAM is a rare but serious lung disease that occurs when an unusual type of cell begins to grow out of control and spread to restricted areas in the body, including the lungs, kidneys, lymph nodes and vessels.

In the first study, 918 LAM patients in North America were surveyed to determine who participated in clinical trials and why. Of the 918 surveyed, 263 patients responded.

"Age, disease duration, use of oxygen therapy and disease presentation without chest pain were associated with trial participation, but the desire to help others with similar health problems was at the top of list," says Kinder, also director of the Interstitial Lung Disease Center at UC.

Results showed that 16 percent of LAM patient respondents participated in a clinical trial, but 85 percent of those people participated to help future patients.

In addition, results showed that the usual barriers to trial participation, like time constraints, risk of taking a placebo and geographic location, were found to be less important for LAM patients.

In a separate study, Kinder and colleagues found that it is cost-effective to do CT scan screening of non-smoking women, ages 25-54, who come to the emergency room for the first time with a collapsed lungan early predictor of LAMin order to diagnose and treat those with the illness.

"A major contributor to morbidity in patients with LAM is spontaneous pneumothorax, or a collapsed lung," Kinder says. "Seventy percent of patients with LAM will have at least one and most will have one or more recurrences. Due to lack of awareness and non-specific nature of most symptoms, the diagnosis of LAM is often delayed for several years into the disease.

"A CT scan for women of child-bearing age who experience a collapsed lung could help with a faster diagnosis, thereby improving outcomes."

Kinder says the results of these studies can help identify the disease in its early stages and find more effective treatments for patients with LAM.

"The more quickly we can detect the illness, the better chance a patient has of prolonging her life in addition to introducing the patient to novel therapies through clinical trials, which could help others as well," he says.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Traumatic brain injury haunts children for years with variety of functional problems: Two studies
2. Review finds conflicts of interest in many cancer studies
3. Studies Report Use of USGI Medicals Incisionless Operating Platform(TM) (IOP) in Numerous Incisionless Surgical Procedures
4. Physicians Conduct Research Studies in Minutes, Not Months, at Montefiore Medical Center
5. Kessler Foundation Research Center Presented Two Studies on Post-stroke Spatial Neglect at American Academy of Neurology
6. Studies uncover high and often overlooked costs associated with epilepsy
7. Are we cherry picking participants for studies of antidepressants?
8. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
9. Pharos Innovations and Clients to Showcase Three Client Case Studies at Upcoming ATA Conference
10. Gene Studies Reveal Cancers Secrets
11. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/26/2016)... , ... June 27, 2016 , ... Quality metrics are ... in many ways they remain in the eye of the beholder, according to experts ... publication of The American Journal of Managed Care. For the full issue, click ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
Breaking Medicine Technology: